Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
Prostate Cancer Theranostics & Imaging Centre of Excellence, Peter MacCallum Cancer Centre, Melbourne 3000, Australia.
Future Oncol. 2021 Sep;17(27):3637-3644. doi: 10.2217/fon-2020-1209. Epub 2021 Jul 6.
Despite the remarkable achievements in treating metastatic prostate cancer over the last two decades, castrate-resistant status is still considered the lethal stage of the disease. Theranostics combines a targeting compound (ligand) with a therapeutic radioisotope (radioactive particle) injected into the blood to target the cancer cells. The most studied radioligand is Lu-PSMA-617, which targets PSMA, a protein found in prostate cancer cells. This new approach has shown promising results in treating metastatic castration-resistant prostate cancer. Currently, many trials are using PSMA-targeting radioligands in combination with conventional therapies in advanced prostate cancer or even in the earlier stages of the disease. Other preclinical trials are exploring the possibility of using newer ligands or radioisotopes to treat prostate cancer to increase the specificity and efficacy of this treatment.
尽管在过去二十年中，在治疗转移性前列腺癌方面取得了显著成就，但去势抵抗状态仍被认为是该病的致命阶段。治疗性诊断结合了一种靶向化合物（配体）和一种放射性同位素（放射性粒子），注入血液中以靶向癌细胞。研究最多的放射性配体是 Lu-PSMA-617，它靶向 PSMA，一种在前列腺癌细胞中发现的蛋白质。这种新方法在治疗转移性去势抵抗性前列腺癌方面显示出了有希望的结果。目前，许多试验正在将 PSMA 靶向放射性配体与晚期前列腺癌的常规疗法结合使用，甚至在疾病的早期阶段也在使用。其他临床前试验正在探索使用更新的配体或放射性同位素治疗前列腺癌的可能性，以提高这种治疗的特异性和疗效。
